Drugs that contain Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir
1. Drug name - VIEKIRA PAK (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Sep, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
| CN103819537A | ABBVIE INC | Anti-Viral Compounds |
May, 2017
(5 years ago) | |
| CN104628655A | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Jul, 2017
(5 years ago) | |
| CN104193729A | ABBVIE INC | Antiviral Compound |
Sep, 2017
(5 years ago) | |
| CN104628654A | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Oct, 2017
(4 years ago) | |
| CN106986861A | ABBVIE INC | Antiviral Compound |
Jun, 2020
(2 years ago) | |
| CN103819459B | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103819459A | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN102641271B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Aug, 2021
(1 year, 1 month ago) | |
| CN102641271A | ABBVIE INC | Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound |
Aug, 2021
(1 year, 1 month ago) | |
| CN102746240B | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Aug, 2021
(1 year, 1 month ago) | |
| CN102746240A | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Aug, 2021
(1 year, 1 month ago) | |
| CN101842360B | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Sep, 2028
(5 years from now) | |
| CN101842360A | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| CN101775017A | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN101775017B | ABBVIE INC | Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN103172620B | ABBVIE INC | Antiviral Compound |
Jun, 2030
(7 years from now) | |
| CN103172620A | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN102333772B | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN102333772A | ABBVIE INC | Anti-Viral Compounds |
Jun, 2030
(7 years from now) | |
| CN103209686B | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209686A | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103153988A | ABBVIE INC | Anti-Viral Compounds |
Oct, 2031
(9 years from now) | |
| CN103153988B | ABBVIE INC | Antiviral Compound |
Oct, 2031
(9 years from now) | |
| CN103354808B | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103354808A | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103596941B | ABBVIE INC | Antiviral Compounds |
Feb, 2032
(9 years from now) | |
| CN103596941A | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| CN108350016B | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| CN108350016A | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| IN200907222P1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| IN287227B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2954892A1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2954892B1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2368882A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2639226A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2368882B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2639226B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2805726B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468285B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468285A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2340029B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2203431B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Jan, 2030
(7 years from now) | |
| EP2340029A4 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2203431A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Jan, 2030
(7 years from now) | |
| EP2340029A2 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2455376B1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2337781B1 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2455376A1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2628481B1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2337781A2 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2628481A1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2368890B9 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890A1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890B1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2579854B1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854A1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854B2 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2692346B1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2692346A1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2678334B1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| EP2678334A1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(6 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US10201542 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(11 years from now) | |
| US9629841 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(11 years from now) | |
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 250MG BASE;12.5MG, 75MG, 50MG | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.